133 related articles for article (PubMed ID: 17501698)
21. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
22. Molecular therapy of colorectal cancer: progress and future directions.
Weng W; Feng J; Qin H; Ma Y
Int J Cancer; 2015 Feb; 136(3):493-502. PubMed ID: 24420815
[TBL] [Abstract][Full Text] [Related]
23. Nicotine-induced phosphorylation of Akt through epidermal growth factor receptor and Src in PC12h cells.
Nakayama H; Numakawa T; Ikeuchi T
J Neurochem; 2002 Dec; 83(6):1372-9. PubMed ID: 12472891
[TBL] [Abstract][Full Text] [Related]
24. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Warner SL; Gray PJ; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
26. 4'-hydroxywogonin inhibits colorectal cancer angiogenesis by disrupting PI3K/AKT signaling.
Sun D; Zhang F; Qian J; Shen W; Fan H; Tan J; Li L; Xu C; Yang Y; Cheng H
Chem Biol Interact; 2018 Dec; 296():26-33. PubMed ID: 30217479
[TBL] [Abstract][Full Text] [Related]
27. Novel Tyrosine Kinase Targets in Urothelial Carcinoma.
Torres-Jiménez J; Albarrán-Fernández V; Pozas J; Román-Gil MS; Esteban-Villarrubia J; Carrato A; Rosero A; Grande E; Alonso-Gordoa T; Molina-Cerrillo J
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451055
[TBL] [Abstract][Full Text] [Related]
28. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
29. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
30. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
31. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
32. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
Austreid E; Lonning PE; Eikesdal HP
Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
[TBL] [Abstract][Full Text] [Related]
33. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
34. PI3K/Akt/mTOR pathway as a target for cancer therapy.
Morgensztern D; McLeod HL
Anticancer Drugs; 2005 Sep; 16(8):797-803. PubMed ID: 16096426
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.
Silvestris N; Vincenzi B; Brunetti AE; Loupakis F; Dell'Aquila E; Russo A; Scartozzi M; Giampieri R; Cascinu S; Lorusso V; Tonini G; Falcone A; Santini D
Pharmacogenomics; 2014 Sep; 15(13):1701-15. PubMed ID: 25410895
[TBL] [Abstract][Full Text] [Related]
36. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
Li Q; Zhu GD
Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
[TBL] [Abstract][Full Text] [Related]
37. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
38. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
39. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
[TBL] [Abstract][Full Text] [Related]
40. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
Papadimitrakopoulou V; Adjei AA
J Thorac Oncol; 2006 Sep; 1(7):749-51. PubMed ID: 17409953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
